Ignite Planners LLC Purchases 62 Shares of Eli Lilly and Company (NYSE:LLY)

Ignite Planners LLC raised its position in Eli Lilly and Company (NYSE:LLYGet Rating) by 4.9% in the 2nd quarter, Holdings Channel reports. The firm owned 1,337 shares of the company’s stock after buying an additional 62 shares during the period. Ignite Planners LLC’s holdings in Eli Lilly and were worth $438,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Eli Lilly and in the fourth quarter valued at approximately $2,213,765,000. Capital World Investors boosted its holdings in shares of Eli Lilly and by 17.0% in the first quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock valued at $6,402,838,000 after buying an additional 3,242,548 shares during the period. Capital International Investors boosted its holdings in shares of Eli Lilly and by 30.5% in the first quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock valued at $2,532,024,000 after buying an additional 2,063,557 shares during the period. 1832 Asset Management L.P. boosted its holdings in shares of Eli Lilly and by 2,999.1% in the first quarter. 1832 Asset Management L.P. now owns 1,621,696 shares of the company’s stock valued at $458,118,000 after buying an additional 1,569,368 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Eli Lilly and by 38.5% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,525,748 shares of the company’s stock valued at $1,254,743,000 after buying an additional 1,257,817 shares during the period. Institutional investors own 82.45% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several research analyst reports. StockNews.com upgraded shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 14th. Morgan Stanley increased their target price on shares of Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a report on Wednesday, September 7th. BMO Capital Markets increased their target price on shares of Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a report on Tuesday, September 6th. Citigroup increased their target price on shares of Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. Finally, Barclays increased their target price on shares of Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a report on Thursday, July 7th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $332.19.

Eli Lilly and Stock Performance

Shares of LLY traded up $0.04 during trading hours on Friday, hitting $310.91. The company had a trading volume of 116,766 shares, compared to its average volume of 2,237,822. The firm has a market cap of $295.42 billion, a price-to-earnings ratio of 49.58, a PEG ratio of 1.92 and a beta of 0.38. The business has a fifty day moving average of $314.33 and a 200-day moving average of $304.45. Eli Lilly and Company has a 12 month low of $220.20 and a 12 month high of $335.33. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70.

Eli Lilly and (NYSE:LLYGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The company had revenue of $6.49 billion during the quarter, compared to the consensus estimate of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. Eli Lilly and’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.87 earnings per share. Equities analysts anticipate that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 9th. Investors of record on Monday, August 15th were given a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a yield of 1.26%. The ex-dividend date was Friday, August 12th. Eli Lilly and’s dividend payout ratio is 62.52%.

Insider Buying and Selling

In other Eli Lilly and news, Director Jackson P. Tai purchased 656 shares of the stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average cost of $304.19 per share, with a total value of $199,548.64. Following the completion of the transaction, the director now owns 62,857 shares in the company, valued at $19,120,470.83. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Eli Lilly and news, Director Jackson P. Tai purchased 656 shares of the stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average cost of $304.19 per share, with a total value of $199,548.64. Following the completion of the transaction, the director now owns 62,857 shares in the company, valued at $19,120,470.83. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 89,458 shares of the stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the sale, the insider now owns 103,875,441 shares in the company, valued at $34,574,940,536.85. The disclosure for this sale can be found here. Over the last three months, insiders have sold 328,125 shares of company stock valued at $108,581,151. 0.12% of the stock is owned by company insiders.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.